21 | Add to Reading ListSource URL: www.dmas.virginia.govLanguage: English - Date: 2013-08-30 11:26:38
|
|---|
22 | Add to Reading ListSource URL: www.janssenbiotech.comLanguage: English - Date: 2014-01-16 10:51:28
|
|---|
23 | Add to Reading ListSource URL: www.simponi.comLanguage: English - Date: 2014-03-24 06:12:32
|
|---|
24 | Add to Reading ListSource URL: www.simponi.comLanguage: English - Date: 2014-01-19 22:59:49
|
|---|
25![PRIOR AUTHORIZATION POLICY Otezla® (apremilast tablets – Celgene Corporation) To Initiate a Coverage Review, Call[removed]OVERVIEW Otezla, a phosphodiesterase 4 (PDE4) inhibitor, is indicated for treatment of a](https://www.pdfsearch.io/img/f5b43faf1b3a827554f9cb87a9bc264c.jpg "PRIOR AUTHORIZATION POLICY Otezla® (apremilast tablets – Celgene Corporation) To Initiate a Coverage Review, Call[removed]OVERVIEW Otezla, a phosphodiesterase 4 (PDE4) inhibitor, is indicated for treatment of a") | Add to Reading ListSource URL: statehealthplan.state.nc.usLanguage: English - Date: 2014-05-29 15:15:36
|
|---|
26 | Add to Reading ListSource URL: www.janssenaccessone.comLanguage: English - Date: 2012-12-23 00:19:27
|
|---|
27![Xeljanz® (tofacitinib tablets – Pfizer) To Initiate a Coverage Review, Call[removed]OVERVIEW Xeljanz is an inhibitor of the Janus kinases (JAK) pathways approved for the treatment of adults with moderately to s](https://www.pdfsearch.io/img/d0fb44fc0cfd58c072c14c39af31dd5d.jpg "Xeljanz® (tofacitinib tablets – Pfizer) To Initiate a Coverage Review, Call[removed]OVERVIEW Xeljanz is an inhibitor of the Janus kinases (JAK) pathways approved for the treatment of adults with moderately to s") | Add to Reading ListSource URL: statehealthplan.state.nc.usLanguage: English - Date: 2014-08-12 13:02:45
|
|---|
28 | Add to Reading ListSource URL: www.tricare.milLanguage: English - Date: 2009-10-21 16:35:34
|
|---|
29![PRIOR AUTHORIZATION POLICY Simponi™ (golimumab for subcutaneous [SC] injection – Janssen Biotech, Inc.) To Initiate a Coverage Review, Call[removed]OVERVIEW Simponi SC is a recombinant human monoclonal antibod](https://www.pdfsearch.io/img/18c53a89707c782ed5ad5455b7236a36.jpg "PRIOR AUTHORIZATION POLICY Simponi™ (golimumab for subcutaneous [SC] injection – Janssen Biotech, Inc.) To Initiate a Coverage Review, Call[removed]OVERVIEW Simponi SC is a recombinant human monoclonal antibod") | Add to Reading ListSource URL: statehealthplan.state.nc.usLanguage: English - Date: 2014-08-12 13:02:43
|
|---|
30 | Add to Reading ListSource URL: www.simponi.comLanguage: English - Date: 2014-03-24 06:16:38
|
|---|